KR102732013B1 - 모르폴리닐피리돈 화합물 - Google Patents

모르폴리닐피리돈 화합물 Download PDF

Info

Publication number
KR102732013B1
KR102732013B1 KR1020207007564A KR20207007564A KR102732013B1 KR 102732013 B1 KR102732013 B1 KR 102732013B1 KR 1020207007564 A KR1020207007564 A KR 1020207007564A KR 20207007564 A KR20207007564 A KR 20207007564A KR 102732013 B1 KR102732013 B1 KR 102732013B1
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007564A
Other languages
English (en)
Korean (ko)
Other versions
KR20200044025A (ko
Inventor
요한 린드스트룀
리카르드 포스블롬
제니 비크룬트
Original Assignee
스프린트 바이오사이언스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스프린트 바이오사이언스 아베 filed Critical 스프린트 바이오사이언스 아베
Publication of KR20200044025A publication Critical patent/KR20200044025A/ko
Application granted granted Critical
Publication of KR102732013B1 publication Critical patent/KR102732013B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207007564A 2017-08-23 2018-08-23 모르폴리닐피리돈 화합물 Active KR102732013B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS

Publications (2)

Publication Number Publication Date
KR20200044025A KR20200044025A (ko) 2020-04-28
KR102732013B1 true KR102732013B1 (ko) 2024-11-18

Family

ID=59686888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007564A Active KR102732013B1 (ko) 2017-08-23 2018-08-23 모르폴리닐피리돈 화합물

Country Status (20)

Country Link
US (2) US11560374B2 (https=)
EP (2) EP4056569A1 (https=)
JP (2) JP7199736B2 (https=)
KR (1) KR102732013B1 (https=)
CN (3) CN116462674A (https=)
AU (2) AU2018320419B2 (https=)
CY (1) CY1125117T1 (https=)
DK (1) DK3672962T3 (https=)
ES (1) ES2910157T3 (https=)
HR (1) HRP20220497T1 (https=)
HU (1) HUE058661T2 (https=)
IL (3) IL302077A (https=)
LT (1) LT3672962T (https=)
PL (1) PL3672962T3 (https=)
PT (1) PT3672962T (https=)
RS (1) RS63109B1 (https=)
SI (1) SI3672962T1 (https=)
SM (1) SMT202200169T1 (https=)
TW (2) TW202348601A (https=)
WO (1) WO2019038390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200038A1 (en) * 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
EP4251165A1 (en) * 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
WO2022115562A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017140843A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2017140841A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820654B2 (en) * 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
DK2655375T3 (en) * 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
JP6074043B2 (ja) * 2013-08-29 2017-02-01 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
WO2017009751A1 (en) * 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017140843A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2017140841A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Also Published As

Publication number Publication date
AU2018320419B2 (en) 2023-09-28
RU2020110506A (ru) 2021-09-23
IL292489B2 (en) 2023-09-01
IL272815A (en) 2020-04-30
SI3672962T1 (sl) 2022-06-30
US20200361922A1 (en) 2020-11-19
JP7199736B2 (ja) 2023-01-06
CN116462674A (zh) 2023-07-21
HUE058661T2 (hu) 2022-09-28
DK3672962T3 (da) 2022-05-02
TW202348601A (zh) 2023-12-16
CN111108102A (zh) 2020-05-05
JP2020531485A (ja) 2020-11-05
IL292489A (en) 2022-06-01
SMT202200169T1 (it) 2022-05-12
US20230234949A1 (en) 2023-07-27
JP2023021268A (ja) 2023-02-10
RU2020110506A3 (https=) 2022-02-22
KR20200044025A (ko) 2020-04-28
RS63109B1 (sr) 2022-04-29
CY1125117T1 (el) 2024-12-13
IL302077A (en) 2023-06-01
TW201912161A (zh) 2019-04-01
AU2023285995A1 (en) 2024-01-25
EP3672962A1 (en) 2020-07-01
IL272815B (en) 2022-06-01
CA3073142A1 (en) 2019-02-28
PL3672962T3 (pl) 2022-05-02
CN116444510A (zh) 2023-07-18
IL292489B1 (en) 2023-05-01
LT3672962T (lt) 2022-05-10
EP4056569A1 (en) 2022-09-14
HRP20220497T1 (hr) 2022-05-27
PT3672962T (pt) 2022-04-12
US11560374B2 (en) 2023-01-24
AU2018320419A1 (en) 2020-04-09
EP3672962B1 (en) 2022-01-26
ES2910157T3 (es) 2022-05-11
CN111108102B (zh) 2023-04-28
WO2019038390A1 (en) 2019-02-28
TWI803511B (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
ES2821400T3 (es) Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes
US20230234949A1 (en) Morpholinylpyridone compounds
KR102730718B1 (ko) 피리딜피리돈 화합물
KR102731945B1 (ko) 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물
CA3073142C (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40079060A (en) Morpholinylpyridone compounds
HK40030345B (en) Morpholinylpyridone compounds
CA3015045C (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210820

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231026

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241014

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241114

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241114

End annual number: 3

Start annual number: 1

PG1601 Publication of registration